JP2022521410A - 最適化されたワクチン組成物およびその製造方法 - Google Patents

最適化されたワクチン組成物およびその製造方法 Download PDF

Info

Publication number
JP2022521410A
JP2022521410A JP2021549435A JP2021549435A JP2022521410A JP 2022521410 A JP2022521410 A JP 2022521410A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2021549435 A JP2021549435 A JP 2021549435A JP 2022521410 A JP2022521410 A JP 2022521410A
Authority
JP
Japan
Prior art keywords
antigen
vaccine
antigens
clade
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521410A5 (https=
Inventor
ジェイコブ グランヴィル，
サラ アイブズ，
マイケル イザキー，
サウサン ユーセフ，
ジャン－フィリップ ビュルケルト，
Original Assignee
センティヴァックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センティヴァックス， インコーポレイテッド filed Critical センティヴァックス， インコーポレイテッド
Publication of JP2022521410A publication Critical patent/JP2022521410A/ja
Publication of JP2022521410A5 publication Critical patent/JP2022521410A5/ja
Priority to JP2025056539A priority Critical patent/JP2025098224A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021549435A 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法 Pending JP2022521410A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056539A JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962808760P 2019-02-21 2019-02-21
US62/808,760 2019-02-21
US201962817902P 2019-03-13 2019-03-13
US62/817,902 2019-03-13
PCT/US2020/019367 WO2020172635A1 (en) 2019-02-21 2020-02-21 Optimized vaccine compositions and methods for making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056539A Division JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Publications (2)

Publication Number Publication Date
JP2022521410A true JP2022521410A (ja) 2022-04-07
JP2022521410A5 JP2022521410A5 (https=) 2023-09-07

Family

ID=72145134

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549435A Pending JP2022521410A (ja) 2019-02-21 2020-02-21 最適化されたワクチン組成物およびその製造方法
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056539A Pending JP2025098224A (ja) 2019-02-21 2025-03-28 最適化されたワクチン組成物およびその製造方法

Country Status (5)

Country Link
US (1) US20220088175A1 (https=)
EP (2) EP4729125A2 (https=)
JP (2) JP2022521410A (https=)
CN (1) CN113747915A (https=)
WO (1) WO2020172635A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217714B (zh) * 2022-10-14 2024-03-15 华中农业大学 一种全猪源pedv单克隆抗体及其抗原表位
WO2024102923A1 (en) * 2022-11-09 2024-05-16 Centivax, Inc. Low dose vaccine compositions
WO2024220936A1 (en) * 2023-04-20 2024-10-24 Centivax, Inc. Vaccine compositions and uses thereof
CN119219767B (zh) * 2023-06-29 2025-05-27 华中农业大学 两株全猪源pedv单克隆中和抗体及其用途
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520708T1 (de) * 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
WO2008054540A2 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
US10059746B2 (en) * 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
AU2012271336B2 (en) * 2011-06-17 2017-03-02 University Of Tennessee Research Foundation Group A streptococcus multivalent vaccine
EP3937179A1 (en) * 2012-05-21 2022-01-12 Distributed Bio Inc Epitope focusing by variable effective antigen surface concentration
US10736956B2 (en) * 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3307311A4 (en) * 2015-06-15 2019-02-13 Emory University MULTIVALENT ENTOVIRUS VACCINE COMPOSITIONS AND RELATED USES
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073340A1 (en) * 2016-10-19 2018-04-26 Redbiotec Ag Influenza virus vaccine

Also Published As

Publication number Publication date
EP3927372A1 (en) 2021-12-29
WO2020172635A1 (en) 2020-08-27
EP4729125A2 (en) 2026-04-22
EP3927372A4 (en) 2023-01-25
US20220088175A1 (en) 2022-03-24
JP2025098224A (ja) 2025-07-01
CN113747915A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
Pillet et al. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial
JP2022521410A (ja) 最適化されたワクチン組成物およびその製造方法
Webster et al. Continuing challenges in influenza
US10793834B2 (en) Live-attenuated virus and methods of production and use
Dundon et al. Progressive truncation of the Non-Structural 1 gene of H7N1 avian influenza viruses following extensive circulation in poultry
JP2016509609A (ja) Ｈ５インフルエンザのヒトへの適応
WO2019191261A1 (en) Methods of generating broadly protective vaccine compositions comprising neuraminidase
CA2811023A1 (en) Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
CN103328629A (zh) 针对大流行性甲型流感病毒h1n1的新型疫苗
Rimmelzwaan et al. Immune responses to infection with H5N1 influenza virus
JP7479424B2 (ja) 改変インフルエンザヘマグルチニンポリペプチドの修飾
JP2021519084A (ja) ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
Nishiyama et al. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses
US10301359B2 (en) Human adaptation of H3 influenza
US20120156242A1 (en) An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody
Arevalo Of Mice, Ferrets, And Men: From Original Antigenic Sin To A New Universal Influenza Virus Vaccine Candidate
EA051755B1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328